Immunome, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: -63.3%
EBITDA: -28.8%
EBIT: -9.5%
EPS: +24.8%
Free cash flow: -27.2%
Operating cash flow: -28.7%

Forward estimates

Revenue: +531.4%
EBITDA: +102.3%
EPS: +1.3%

Three-year CAGR

Revenue: -29.6%
EBITDA: -38.4%
EBIT: +30.0%
Net income: +27.5%
EPS: +51.4%
Free cash flow: -22.1%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.